MEDICUS PHARMA LTD. Deferred Costs, Noncurrent
MEDICUS PHARMA LTD. (MDCX) had Deferred Costs, Noncurrent of $716.90 thousand as of 2025-06-30, per its 10-Q filed 2025-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2025-08-11
- 2025-06-30: Deferred Costs, Noncurrent $716.90K.
- 2025-03-31: Deferred Costs, Noncurrent $325.00K.
- 2024-12-31: Deferred Costs, Noncurrent $0.00.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2025-06-30 | $716.90K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $325.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $0.00 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |